COVID-19 (SARS-CoV-2 infection) in lymphoma patients: A review

Table 3 Case reports and case series of coronavirus disease 2019 infection in lymphoma patients

Ref.	No. of patients described	Sex	Age	Details on lymphoma diagnosis	Details on lymphoma treatment	Outcome of COVID-19 infection	Global outcome
Li et al[61], 2020	1	M	26 yr	PMLBCL	R-DA-EPOCH	Recovered	Alive
Tepasse et al[62], 2020	2	M	65 yr	DLBCL with CNS relapse	R-DeVIC	Not recovered	Dead
		M	66 yr	MCL in CR	Rituximab maintenance	Not recovered	Dead
O'Kelly et al[63], 2020	1			cHL second relapse	Pembrolizumab	Recovered	Alive
Baang et al[64], 2021	1	M	60 yr	Relapsed/Refractory MCL	R-CHOP	Recovered	Alive
Moore et al[65], 2020	1	F	63 yr	NHL	Obinotuzumab maintenance	Recovered	Alive
Alsuliman et al[66], 2020	2	M	71 yr	MCL relapsed	Ibrutinib	Recovered	Alive
		M	NR	MCL relapsed	Ibrutinib	Recovered	Alive
Hoffmann et al[67], 2021	3	F	68 yr	DLBCL, FL	R-CHOP	Recovered	Alive
		M	60 yr	DLBCL, FL	R-ICE	Not recovered	Dead
		M	75 yr	DLBCL	R-CHOP	Not recovered	Dead
Yonal-hindilerden et al[68], 2021	1	F	55 yr	Relapsed/Refractory cHL	Brentuximab	Not recovered	Dead
Fujii et al[69], 2021	1	M	43 yr	cHL	A + AVD	Recovered	Alive
Kamel, 2021	1	M	58 yr	ALCL	None	Not recovered	Dead
Santana et al[70], 2021	1	F	47 yr	FL	Rituximab maintenance	Recovered	Alive
Velier et al[71], 2021	1	F	61 yr	WM	None	Recovered	Dead
Pelcovits et al[72], 2021	1	M	43 yr	High Grade B Cell Lymphoma, NOS	R-CODOX-M/IVAC	Recovered	Alive
Otsuka et al[73], 2020	1	M	56 yr	MCL	R-hyper CVAD/MA	Not recovered	Dead

A + AVD: Brentuximab vedotin, dacarbazine, doxorubicin, vinblastine; ALCL: Anaplastic large-cell lymphoma; cHL: Classic Hodgkin lymphoma; CNS: Cerebral nervous system; COVID-19: Coronavirus disease 2019; CR: Complete remission; DLBCL: Diffuse large B-cell lymphoma; F: Female; FL: Follicular lymphoma; M: Male; MCL: Mantle cell lymphoma; NHL: Non-Hodgkin lymphoma; NOS: Not otherwise specified; PMLBCL: Primary mediastinal large B-cell lymphoma; R-CHOP: Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; R-CODOX-M/IVAC: Rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate alternating with ifosfamide, etoposide and cytarabine; R-DA-EPOCH: Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab; R-DeVIC: Rituximab, dexamethasone, etoposide, ifosfamide carboplatin; R-hyper CVAD/MA: Rituximab/cyclophosphamide/vincristine sulfate/doxorubicin and hydrochloride/dexamethasone/methotrexate/cytarabine; R-ICE: Rituximab, ifosfamide, carboplatin and etoposide; WM: Waldenstrom macroglobulinemia.